BR112013033617A2 - novos marcadores de diferenciação de th17 para acne e usos dos mesmos - Google Patents

novos marcadores de diferenciação de th17 para acne e usos dos mesmos

Info

Publication number
BR112013033617A2
BR112013033617A2 BR112013033617A BR112013033617A BR112013033617A2 BR 112013033617 A2 BR112013033617 A2 BR 112013033617A2 BR 112013033617 A BR112013033617 A BR 112013033617A BR 112013033617 A BR112013033617 A BR 112013033617A BR 112013033617 A2 BR112013033617 A2 BR 112013033617A2
Authority
BR
Brazil
Prior art keywords
acne
new
differentiation markers
markers
differentiation
Prior art date
Application number
BR112013033617A
Other languages
English (en)
Other versions
BR112013033617B1 (pt
Inventor
Carlavan Isabelle
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of BR112013033617A2 publication Critical patent/BR112013033617A2/pt
Publication of BR112013033617B1 publication Critical patent/BR112013033617B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R31/00—Coupling parts supported only by co-operation with counterpart
    • H01R31/02—Intermediate parts for distributing energy to two or more circuits in parallel, e.g. splitter
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02M—APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF
    • H02M3/00—Conversion of dc power input into dc power output
    • H02M3/02—Conversion of dc power input into dc power output without intermediate conversion into ac
    • H02M3/04—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters
    • H02M3/10—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode
    • H02M3/145—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal
    • H02M3/155—Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
    • H01R13/66—Structural association with built-in electrical component
    • H01R13/665—Structural association with built-in electrical component with built-in electronic circuit
    • H01R13/6675—Structural association with built-in electrical component with built-in electronic circuit with built-in power supply

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
BR112013033617-0A 2011-06-27 2012-06-25 Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17 BR112013033617B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501363P 2011-06-27 2011-06-27
US61/501,363 2011-06-27
PCT/EP2012/062257 WO2013000869A1 (en) 2011-06-27 2012-06-25 New th17 differentiation markers for acne and uses thereof

Publications (2)

Publication Number Publication Date
BR112013033617A2 true BR112013033617A2 (pt) 2017-03-01
BR112013033617B1 BR112013033617B1 (pt) 2021-10-26

Family

ID=46331344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033617-0A BR112013033617B1 (pt) 2011-06-27 2012-06-25 Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17

Country Status (11)

Country Link
US (2) US20140235475A1 (pt)
EP (1) EP2723889B1 (pt)
JP (2) JP6279467B2 (pt)
KR (1) KR102066295B1 (pt)
CN (2) CN103930565B (pt)
AU (2) AU2012277951C1 (pt)
BR (1) BR112013033617B1 (pt)
CA (1) CA2840403A1 (pt)
IN (1) IN2014CN00586A (pt)
MX (1) MX349048B (pt)
WO (1) WO2013000869A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6366503B2 (ja) * 2011-06-27 2018-08-01 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用
UA117913C2 (uk) 2012-05-31 2018-10-25 Фінекс Фармас'Ютікалс Аг КАРБОКСАМІД- АБО СУЛЬФОНАМІДЗАМІЩЕНІ ТІАЗОЛИ ТА СПОРІДНЕНІ ПОХІДНІ ЯК МОДУЛЯТОРИ ОРФАНОВОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2886661A1 (en) * 2013-12-19 2015-06-24 King's College London OVOL1 as a new marker for moderate to severe acne
US10376475B2 (en) * 2014-12-12 2019-08-13 Dermavant Sciences GmbH Method of use
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
JO3680B1 (ar) 2015-05-21 2020-08-27 Dermavant Sciences GmbH تركيبات صيدلانية موضعية
KR102359437B1 (ko) * 2016-05-30 2022-02-09 (주)아모레퍼시픽 항여드름 물질을 스크리닝하는 방법
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
FR3067593B1 (fr) * 2017-06-20 2019-12-20 Jean-Noel Thorel Utilisation d'extraits de plantes pour le traitement dermatocosmetique des etats inflammatoires lies a une surproduction de il-17
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
JP2022554046A (ja) * 2020-08-10 2022-12-28 カティス バイオメディカル リサーチ センター マイクロニードルパッチを含む最小侵襲的皮膚状態の診断キット
KR102216927B1 (ko) * 2020-08-11 2021-02-18 주식회사 큐티스의생명연구센터 마이크로니들 패치를 포함하는 최소 침습적 화장품여드름 예측 키트 및 화장품여드름 예측용 바이오마커

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US20020102232A1 (en) 2000-05-11 2002-08-01 Chang Tse W. Compositions and methods for induction of active autoimmunity
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
ES2503765T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
CA2595169A1 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
DE102005057996B4 (de) 2005-12-05 2008-08-28 Gebr. Brasseler Gmbh & Co. Kg Wurzelkanalinstrument
EP2124058B1 (en) * 2006-01-05 2014-03-05 Galderma Research & Development Acne diagnostic method by using lesions biomarkers and in vitro screening method for identifying modulators thereof
US8603978B2 (en) 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
WO2008156644A2 (en) 2007-06-14 2008-12-24 Frank David A Stat modulators
CA2692037A1 (en) 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
FR2923610B1 (fr) 2007-11-14 2009-11-27 Galderma Res & Dev Methode non-invasive de recueil de donnees biologiques pour l'etablissement d'un diagnostic d'une pathologie cutanee.
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
WO2010066641A1 (en) 2008-12-11 2010-06-17 Unilever Plc Oral composition
US20100166784A1 (en) 2008-12-30 2010-07-01 The Washington University Method and compositions for modulating th17 cell development
CN101580874B (zh) * 2009-03-17 2012-03-21 江苏大学 一种人外周血RORγt转录本荧光定量PCR检测方法
US20120142544A1 (en) 2009-06-02 2012-06-07 University Of Miami Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
GB0912481D0 (en) 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor

Also Published As

Publication number Publication date
CN103930565B (zh) 2017-06-30
CA2840403A1 (en) 2013-01-03
JP6279467B2 (ja) 2018-02-14
CN107012201A (zh) 2017-08-04
AU2012277951A1 (en) 2014-02-20
US20160237503A1 (en) 2016-08-18
IN2014CN00586A (pt) 2015-04-03
JP2014519855A (ja) 2014-08-21
WO2013000869A1 (en) 2013-01-03
CN103930565A (zh) 2014-07-16
EP2723889A1 (en) 2014-04-30
KR20140047674A (ko) 2014-04-22
MX2014000169A (es) 2014-02-19
AU2017202172B2 (en) 2018-11-08
MX349048B (es) 2017-07-07
US20140235475A1 (en) 2014-08-21
AU2012277951A2 (en) 2014-03-20
EP2723889B1 (en) 2019-11-06
AU2017202172A1 (en) 2017-04-20
AU2012277951B2 (en) 2017-01-19
US10760129B2 (en) 2020-09-01
AU2012277951C1 (en) 2019-02-21
JP2017051198A (ja) 2017-03-16
BR112013033617B1 (pt) 2021-10-26
KR102066295B1 (ko) 2020-01-14

Similar Documents

Publication Publication Date Title
BR112013033617A2 (pt) novos marcadores de diferenciação de th17 para acne e usos dos mesmos
BR112015000997A2 (pt) marcador magnético para localização cirúrgica
BR112014007789A2 (pt) sistemas e métodos para análise biológica
BR112014023162A2 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
BR112013029163A2 (pt) modulação quinase e indicações dos mesmos
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
BR112013033098A2 (pt) inibidores de glicosidade seletivos e usos dos mesmos
CO6920264A2 (es) Sistema para vientos
BRDI7106210S (pt) Configuração aplicada para lâmina para microscópio
BR112012025697A2 (pt) "dispositivo e método para conjunto estrutural"
BR112013018656A2 (pt) sistemas e métodos para maximização de uso de amostra
BR112013000372A2 (pt) conjunto de ejeção de fluído e método para circular fluído
BR112013013888A2 (pt) sistemas e métodos para monitoramento de poço
BR112013029813A2 (pt) métodos e dispositivos para distribuição de conteúdo
BR112013032064A2 (pt) sistema de refrigeração e métodos para refrigeração
BR112013028398A2 (pt) distribuidores de líquidos e métodos para fabricaçãodos mesmos
BR112013006131A2 (pt) inibidores de notum pectinacetilesterase e métodos para sua utilização
BR112014007865A2 (pt) aparelho para detecção microscópica de dureza
BR112013012376A2 (pt) sistemas e métodos de contramedida para slug
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
BR112014016744A8 (pt) agentes de ligação para moléculas-alvo intracelulares
BR112014008203A2 (pt) métodos e sistemas para identificação e tratamento de tumores sensíveis á antiprogestina
BR112014000894A2 (pt) marcadores de ssr para plantas e seus usos
BR302012000184S1 (pt) "configuração aplicada em aparelho para laboratório"
BRDI7105383S (pt) Configuração aplicada em banda de rodagem para pneumático

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2728 DE 18-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.